Core Viewpoint - The stock of Innovent Biologics-B (02591) rose over 3%, reaching HKD 32, following the announcement that its innovative drug, Icosapent Ethyl (brand name: Yinuo Qing®), has been included in the 2025 National Medical Insurance Drug List in China, marking a significant step towards making diabetes treatment more accessible [1]. Group 1: Company Developments - Innovent Biologics' Icosapent Ethyl is the first long-acting human GLP-1 receptor agonist (GLP-1RA) developed in China, aimed at controlling blood sugar levels in adult patients with type 2 diabetes [1]. - The drug will officially be implemented in the national insurance scheme starting January 1, 2026, enhancing its market accessibility [1]. Group 2: Industry Impact - The inclusion of Icosapent Ethyl in the national insurance list aligns with the "Healthy China 2030" initiative, which aims to advance diabetes prevention and treatment [1]. - The National Guidelines for Diabetes Prevention and Management (2025) classify Icosapent Ethyl as a GLP-1RA injectable medication, providing a policy framework for its use in primary healthcare settings [1]. - The guidelines highlight GLP-1RA as a crucial treatment option for adult type 2 diabetes patients with comorbidities such as atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), and those needing weight management [1].

Core Insights - The stock price of Sinocare Inc. (02591) increased by 5.37%, currently trading at HKD 32.60, with a transaction volume of HKD 33.25 million [1][4] - The first domestically developed ultra-long-acting human GLP-1 receptor agonist, Icosapent Ethyl (brand name: Yinuo Qing®), has been officially included in the 2025 National Medical Insurance Drug List, effective from January 1, 2026, aimed at controlling blood sugar in adult patients with type 2 diabetes [1][4] - This inclusion marks a significant step towards the accessibility of innovative diabetes treatments in China, aligning with the "Healthy China 2030" initiative [1][4] Industry Developments - The National Guidelines for Diabetes Prevention and Control (2025) have classified Icosapent Ethyl as a GLP-1 receptor agonist injectable, providing direct policy and regulatory support for its use in primary healthcare institutions [1][4] - The guidelines emphasize the importance of GLP-1 receptor agonists as a treatment option for adult type 2 diabetes patients with comorbidities such as atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), and those requiring weight management [1][4]

Core Viewpoint - The inclusion of the innovative long-acting human GLP-1 receptor agonist, Icosapent Ethyl (brand name: Yinuo Qing), in the 2025 National Medical Insurance Drug List marks a significant step towards making diabetes treatment more accessible in China, aligning with the "Healthy China 2030" initiative [1] Group 1: Company Developments - Yinuo Pharmaceutical-B (02591) saw its stock price increase by 3.43%, reaching HKD 32, with a trading volume of HKD 20.74 million [1] - The company’s product, Icosapent Ethyl, is now recognized as the first domestically developed long-acting GLP-1 receptor agonist in China [1] Group 2: Industry Impact - The inclusion of Icosapent Ethyl in the national insurance list is aimed at improving the accessibility of innovative diabetes medications [1] - The 2025 National Guidelines for Diabetes Prevention and Management highlight Icosapent Ethyl as a key treatment option for adult patients with type 2 diabetes, especially those with cardiovascular disease risk factors, heart failure, chronic kidney disease, and obesity [1]